RE:RE:RE:RE:RE:Gilles destroyer of shareholders"For the last sevearl years Gilles has been babbling about how we had sufficient funds to develope the pipeline and now suddenly that isnt the case anymore."
There is sufficient funds to develop the pipeline through the next key milestones. He wanted $40 million for a PGX-YBG immune booster plant and you know it. There was never enough for that. The biotech market window closed due to the worst biotech market in history. If $40 million was needed for the PGX-YBG immune booster plant how much would be optimally needed for a PGX-YBG plant to support a CoQ10 partner. At the AGM CZO said it was in discussions with serious potential partners. The immune booster market is $1 billion whereas the CoQ10 market is $4 billion Gilles has said. Would CZO ideally have >$100 million in PGX-YBG plants?
"This presents many business growth opportunities for both Ceapro and NATEX as the deployment of several commercial plants is envisioned with each new product." news release
With the completion of the PGX scale-up now underway with Natex CZO is making commercial decisions in very large markets. With gold standard products CZO could have gold standard market share and will need money to achieve this as well as infrastrucuture. The PGX-YBG fibrosis drug is also nearning clinical trials and Avalyn raised $80 million going into its Phase I trial. CZO's wound healing opportunity is also appraching a potential partnership. There is the avenanthramide clinical trial.
CZO is putting in place the resources and capacity to take things to the next level. $10 million cash, a plant in Edmonton, ~40 people, and a TSX-V listing isn't enough for what comes next. CZO brought in Ronnie Miller, from the world's largest biotech company, to help with what comes next.
"Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro, added, “Mr. Miller brings invaluable experience in managing and building international pharmaceutical companies..." news release
“We are thrilled with this exciting transaction to merge with Aeterna and combine two complementary companies and teams, in support of our plan to drive significant growth,” said Ronnie Miller, Chairman of Ceapro. “After careful consideration, we believe this transaction is the best way forward for Ceapro and our valued shareholders.” news release